Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial-derived FABP4 constitutes the majority of basal circulating hormone and regulates lipolysis-driven insulin secretion
Karen E. Inouye, Kacey J. Prentice, Alexandra Lee, Zeqiu B. Wang, Carla Dominguez-Gonzalez, Mu Xian Chen, Jillian K. Riveros, M. Furkan Burak, Grace Y. Lee, Gökhan S. Hotamışlıgil
Karen E. Inouye, Kacey J. Prentice, Alexandra Lee, Zeqiu B. Wang, Carla Dominguez-Gonzalez, Mu Xian Chen, Jillian K. Riveros, M. Furkan Burak, Grace Y. Lee, Gökhan S. Hotamışlıgil
View: Text | PDF
Research Article Endocrinology Metabolism

Endothelial-derived FABP4 constitutes the majority of basal circulating hormone and regulates lipolysis-driven insulin secretion

  • Text
  • PDF
Abstract

Fatty acid binding protein 4 (FABP4) is a lipid chaperone secreted from adipocytes upon stimulation of lipolysis. Circulating FABP4 levels strongly correlate with obesity and metabolic pathologies in experimental models and humans. While adipocytes have been presumed to be the major source of hormonal FABP4, this question has not been addressed definitively in vivo. We generated mice with Fabp4 deletion in cells known to express the gene — adipocytes (Adipo-KO), endothelial cells (Endo-KO), myeloid cells (Myeloid-KO), and the whole body (Total-KO) — to examine the contribution of these cell types to basal and stimulated plasma FABP4 levels. Unexpectedly, baseline plasma FABP4 was not significantly reduced in Adipo-KO mice, whereas Endo-KO mice showed ~87% reduction versus WT controls. In contrast, Adipo-KO mice exhibited ~62% decreased induction of FABP4 responses to lipolysis, while Endo-KO mice showed only mildly decreased induction, indicating that adipocytes are the main source of increases in FABP4 during lipolysis. We did not detect any myeloid contribution to circulating FABP4. Surprisingly, despite the nearly intact induction of FABP4, Endo-KO mice showed blunted lipolysis-induced insulin secretion, identical to Total-KO mice. We conclude that the endothelium is the major source of baseline hormonal FABP4 and is required for the insulin response to lipolysis.

Authors

Karen E. Inouye, Kacey J. Prentice, Alexandra Lee, Zeqiu B. Wang, Carla Dominguez-Gonzalez, Mu Xian Chen, Jillian K. Riveros, M. Furkan Burak, Grace Y. Lee, Gökhan S. Hotamışlıgil

×

Figure 5

Endothelial and adipocyte FABP4 secretion are differentially regulated.

Options: View larger image (or click on image) Download as PowerPoint
Endothelial and adipocyte FABP4 secretion are differentially regulated.
...
(A) Twelve-hour conditioned media FABP4 levels from CD31-isolated endothelial cells from liver, heart, and lungs of WT, Adipo-KO, and Endo-KO mice, normalized to total cellular protein; n = 3 mice/group. (B and C) FABP4 levels in HUVEC lysates and 5-hour conditioned media, normalized to total cellular protein at days 3 through 14 after seeding. Pool of 2 experiments; n = 6/time point. (D) Time-course of cumulative FABP4 levels in media of day 7 HUVECs; n = 4/time point. Inset: Media lactate dehydrogenase (LDH) levels during the same time course. °°°°P < 0.0001, °°°P < 0.001 versus 0 hours by 1-way ANOVA followed by Dunnett’s multiple-comparison test. (E) Effects of the ER-Golgi pathway inhibitor, brefeldin A (BFA), on FABP4 and endothelin-1 (ET-1) secretion from day 11 HUVECs; n = 3/BFA dose. (F) Effects of forskolin (FSK) on FABP4 secretion in HUVECs versus 3T3-L1 adipocytes. n = 3/FSK dose. *P < 0.05 versus HUVEC by 2-way ANOVA followed by Sidak’s multiple-comparison test. (G) Effects of FSK on FABP4 and von Willebrand Factor (vWF) secretion from day 11 HUVECs. FABP4, n = 4/FSK dose; vWF, n = 3/FSK dose. (H) Total FABP4 measured by ELISA in HUVEC cell lysates (CL), conditioned media (CM), and exosomes (Exos) isolated from CM; n = 3. (I) Western blots of FABP4, exosome markers CD-63 and ALiX, and double-membrane protein β-actin in HUVEC cell lysates, conditioned media, and exosomes. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA followed by Sidak’s (A), Tukey’s (B, C, and H), or Dunnett’s (E and G) multiple-comparison test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts